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Background: Prions were first identified as infectious proteins associated with fatal brain diseases in mammals.
However, fungal prions behave as epigenetic regulators that can alter a range of cellular processes. These proteins
propagate as self-perpetuating amyloid aggregates being an example of structural inheritance. The
best-characterized examples are the Sup35 and Ure2 yeast proteins, corresponding to [PSI+] and [URE3]
phenotypes, respectively.
Results: Here we show that both the prion domain of Sup35 (Sup35-NM) and the Ure2 protein (Ure2p) form
inclusion bodies (IBs) displaying amyloid-like properties when expressed in bacteria. These intracellular aggregates
template the conformational change and promote the aggregation of homologous, but not heterologous, soluble
prionogenic molecules. Moreover, in the case of Sup35-NM, purified IBs are able to induce different [PSI+]
phenotypes in yeast, indicating that at least a fraction of the protein embedded in these deposits adopts an
infectious prion fold.
Conclusions: An important feature of prion inheritance is the existence of strains, which are phenotypic variants
encoded by different conformations of the same polypeptide. We show here that the proportion of infected yeast
cells displaying strong and weak [PSI+] phenotypes depends on the conditions under which the prionogenic
aggregates are formed in E. coli, suggesting that bacterial systems might become useful tools to generate prion
strain diversity.
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Mammalian prions cause fatal neurodegenerative disor-
ders, like Creutzfeldt–Jacob disease in humans, bovine
spongiform encephalopathy and scrapie in sheep [1]. In
yeast, several polypeptides can form prions that behave as
dominant non-Mendelian cytoplasmic genetic elements.
The best-characterized yeast prionogenic proteins are
Sup35 and Ure2, which, in their aggregated state, form
two cytosolic inheritable elements named [PSI+] and
[URE3], respectively. Whether this property is detrimental
and prion formation constitutes a pathological yeast trait
or it is, in contrast, associated to beneficial phenotypes is
controversial [2]. The fact that in wild-type yeast, the* Correspondence: rsabate@ub.edu; salvador.ventura@uab.es
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reproduction in any medium, provided the or[PSI+] or [URE3] prions were initially not found was inter-
preted in favour of the first possibility [3,4], but a recent
study by the Lindquist’s group demonstrates that various
yeast prions can be found in several isolates of wild type
yeast [5], favouring thus the second possibility. Regardless
of their cellular effects, both mammalian and fungal prion
proteins are characterized by a high propensity to assem-
ble into amyloid-like aggregates under physiological con-
ditions both in vitro and in the cell [6]. Prions represent a
particular subclass of amyloids for which the aggregation
process becomes self-perpetuating in vivo and therefore
infectious [7]. In vitro, the assembly of prions into amyloid
aggregates displays a characteristic lag phase, which is
abrogated in the presence of preformed fibres [8-10]. This
seeded catalysis of the polymerization reaction underlies
prion conformational replication and infectivity [6]. Re-
constitution of in vivo infectivity from in vitro aggregates
formed by recombinant purified prions has definitively
proven the protein only hypothesis for prion formationral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prion spreadable species [11,12]. Prion assemblies of the
same protein might lead to phenotypically different trans-
missible states or strains [13]. It is suggested that this
phenomenon results from a single protein being able to
adopt multiple misfolded conformations, each one cor-
responding to a specific strain.
The formation of inclusion bodies (IBs) in bacteria
has long been regarded as an unspecific process de-
pending on the establishment of hydrophobic contacts
between partially or totally unfolded species after pro-
tein synthesis at the ribosome [14]. However, an in-
creasing body of evidence indicates that bacterial IBs
share a number of common structural features with the
highly ordered and, in many cases, pathogenic amyloid
fibrils [15-18]. So far, the conformational and functional
characteristics of the IBs formed by prions in bacteria
have been only explored in detail for the HET-s prion of
the filamentous fungus Podospora anserina [19,20]. The
HET-s prion functions in a genetically programmed
cell-death phenomenon, which occurs when two fungal
strains of different genotypes fuse [21]. For this particu-
lar prionogenic protein, the formation of IBs and
amyloid fibrils seems to be a remarkably similar process
as IBs display a highly ordered amyloid-like conform-
ation at the molecular level [19,20], are able to seed the
polymerization of amyloid-fibrils in vitro [19,20] and
turn to be infectious in vivo [20]. This suggests that the
aggregates formed by other prionogenic proteins in bac-
teria might exhibit equal properties. We show here that
this is the case for the yeast prion domain of Sup35
(Sup35-NM) and the Ure2 protein (Ure2p).
Results and discussion
Ure2p and Sup35-NM form β-sheet enriched IBs
We analyzed the cellular distribution of Ure2p and
Sup35-NM proteins when expressed recombinantly in
bacteria at 37°C. Western blotting and densitometry of the
soluble and insoluble fractions indicate that about 50% of
Ure2p and 40% of Sup35-NM recombinant proteins reside
in the insoluble cellular fraction in these conditions
(Figure 1A and C). Accordingly, bacterial cells expressing
these polypeptides form birefringent IBs, located predo-
minantly at the cell poles, as shown by phase contrast
microscopy (Figure 1B and D).
The aggregation of proteins into amyloid fibrils results
in the formation of intermolecular β-sheets [22,23].
Fourier-transform infrared (FT-IR) spectroscopy allows
addressing structural features of protein aggregates
[24,25]. Specifically, the amide I region corresponding to
the absorption of the carbonyl peptide bond group of
the protein main chain is a sensitive marker of the
protein secondary structure. To decipher the secondary
structure in Sup35-NM and Ure2p IBs, we purified themfrom bacterial cell extracts and analyzed their FT-IR
spectra (Figure 2A, B and C). Deconvolution of the ab-
sorbance spectrum in the amide I region for Sup35-NM
and Ure2p IBs permitted to identify the individual sec-
ondary structure components and their relative contri-
bution to the main absorbance signal. Both IBs exhibit
FT-IR bands that can be assigned to the presence of
intermolecular β-sheets (Table 1). These signals are ab-
sent or display a low intensity in the FT-IR of purified,
initially soluble and monomeric, Sup35-NM and Ure2p
species (Figure 2A and B). Therefore, as reported for
other amyloid proteins [15,18,19,26], aggregation of
Sup35-NM and Ure2p into IBs results in the formation
of a supra-molecular structure in which at least part of
the polypeptide chains adopt a disposition similar to this
in amyloids. The IBs of the two yeast prionogenic pro-
teins display, however, certain differences in secondary
structure (Table 1 and Figure 2C); Ure2p IBs being
slighted enriched in intermolecular β-sheet structure
relative to Sup35-NM aggregates. The secondary struc-
ture content of Sup35-NM IBs closely resembles the one
we observed for fibrils under agitation conditions [27]. In
the case of Ure2p IBs, their secondary structure is more
similar to that in fibrils formed under quiescent conditions
[28]. In fact we have shown that, in contrast to Sup35-
NM, the secondary structure content of Ure2p is strongly
dependent on the aggregation conditions [27].
The presence of regular secondary structure inside IBs
implies the existence of cooperative interactions involv-
ing the main and side chains of the polypeptides embed-
ded in these aggregates. To confirm this extent, we used
chemical denaturation with guanidine hydrochloride
(GdnHCl). We have shown before that this approach
allows to approximate the conformational stability of
intracellular aggregates [29]. Ure2p and Sup35-NM IBs
denaturation was measured by monitoring the changes
in absorbance at 350 nm in a GdnHCl range from 0 to
8 M. We calculated [GdnHCl]1/2 for IBs solubilization
under equilibrium conditions (20 h incubation) to be
1.8 M and 2.1 M for Sup35-NM and Ure2p IBs, respect-
ively (Figure 2D). These values are close to the one
observed for HET-s PFD IBs (1.6 M) [19] and in agree-
ment with their relative intermolecular β-sheet content.
The cooperative denaturation transitions observed for
both IBs support the presence of selective contacts in at
least a fraction of the molecules deposited inside them.
Amyloid properties of Sup35-NM and Ure2p IBs
We used the amyloid-specific dyes Congo red (CR),
thioflavin T (Th-T) and S (Th-S) to confirm that the
detected β-sheet secondary structure in Sup35-NM and
Ure2p IBs is organized into an amyloid-like suprastruc-
ture. The absorbance of CR increases and the spectrum
maximum red-shifts to 510 nm in the presence of both
AB D
C
Figure 1 Solubility properties of recombinant Sup35-NM (left panel) and Ure2p (right panel) proteins. (A and C) Western blot of the
soluble and insoluble fractions of cells expressing Sup35-NM and Ure2p at 37°C detected with an anti-histag antibody and quantified by
densitometry using the Quantity-One software (Bio-Rad). (B and D) Localization of cytoplasmic IBs at the poles of cells expressing Sup35-NM and
Ure2p proteins, as imaged by phase contrast microscopy.
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that observed in the presence of the fibrils formed
in vitro by both proteins [27,30,31]. Moreover, the differ-
ence spectra of the dye in the presence and absence of
IBs exhibit the characteristic amyloid band at 541 nm
(Figure 3B).
Th-T fluorescence emission is enhanced in the
presence of yeast prion amyloid fibrils [27,30,31]. The
same behaviour is observed upon incubation of Th-T
with yeast proteins IBs (Figure 3C). The Th-T fluores-
cence at the 480 nm spectral maximum increases 20-
and 40-folds for Sup35-NM and Ure2p IBs, respectively.
Furthermore, binding of Th-S to IBs was visualized by
fluorescence microscopy (Figure 3D). For both IBs, areas
rich in fibrous material were stained with Th-S to yield a
bright green–yellow fluorescence against a dark back-
ground. Therefore, consistently with the secondary
structure data and the existence of selective interactions,
the dye binding results indicate that both IBs possess de-
tectable amounts of amyloid structure.
Sup35-NM and Ure2p IBs selectively seed amyloid
formation
The kinetics of amyloid fibril formation usually results
in a sigmoid curve that reflects a nucleation-dependent
growth mechanism [29]. We have shown previously that
the in vitro assembly of Sup35-NM and Ure2p fibrils
follows this kinetic scheme [27]. The detected lag phase
corresponds to the formation of the initial nuclei onwhich the polymerization or fibril growth would further
spontaneously proceed. Seeded protein polymerization is
a well-established mechanism for in vivo amyloid fibril
formation and underlies prion propagation [32-34]. In
Figure 4, it is shown, the effect of the presence of pre-
formed amyloid Sup35-NM and Ure2p fibrils on the kin-
etics of fibril formation. In the presence of a 10% of
preformed fibrils, the apparent nucleation constant (kn)
increases by three- and five-fold for Sup35-NM and
Ure2p, respectively (Table 2). As a result, the lag phase
of the reaction is shortened by 22 min for Sup35-NM
and by 62 min for Ure2p. As expected, no significant
changes in the apparent elongation constants (ke) were
detected since fibril seeds act preferentially at the nucle-
ation stage.
To test if the detected amyloid-like structures in Sup35-
NM and Ure2p IBs were able to template the conform-
ational conversion of their respective soluble species into
amyloid fibrils, we performed aggregation experiments in
the presence of preformed and purified IBs. The effect
exerted by these aggregates on fibril formation kinetics is
analogous to that promoted by the corresponding fibrillar
states. Their presence do not affect ke but increases kn by
three- and seven-fold for Sup35-NM and Ure2p reactions,
respectively; shortening the respective lag phases in
26 min and 68 min (Figure 4). Interestingly enough, fibrils
and IBs have quantitatively similar effects on the reaction
constants for amyloid formation of yeast prionogenic
proteins (Table 2).
Figure 2 Conformational properties of soluble and aggregated
Sup35-NM and Ure2p proteins. Secondary structure of Sup35-NM
(A) and Ure2p (B) yeast proteins in their soluble forms and inside
the IBs formed at 37°C as determined FT-IR spectroscopy in the
amide I region of the spectrum. Empty circles, solid thick lines and
solid thin line show the absorbance spectra, the sum of individual
spectral components and the inter-molecular β-sheet band,
respectively; note that whereas Sup35-NM and Ure2p IBs display the
typical inter-molecular β-sheet band at 1625–1630 cm-1, this signal is
low or absent in soluble species. (C) Comparative analysis of the
secondary structure of Sup35-NM and Ure2p IBs. Empty circles, solid
thick lines and solid thin lines show the absorbance spectra, the
sum of individual spectral components and the deconvolved
component bands, respectively. (D) Stability of yeast prionogenic IBs
in front of GdnHCl denaturation at equilibrium monitored by
changes in turbidity at 350 nm.
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tion is a specific process that can be seeded by
homologous fibrils, but not by fibrils from unrelated
polypeptides, even if they share a cross β-sheet conform-
ation [35]. To test if this selectivity also applies in the
case of IBs, we performed cross-seeding experiments,
seeding the aggregation reaction of Sup35-NM with pre-
formed Ure2p IBs and vice-versa. Importantly, the
presence of heterologous prionogenic IBs does not affect
the nucleation rates or lag times (Figure 4 and Table 2).Table 1 Secondary structure bands in the absorbance FT-IR sp
18°C 3
Sup35-NM IBs Sup35-NM IBs
Band (cm-1) Area (%) Band (cm-1) Area (%)
1615 4 1617 7
1629 29 1628 21
1652 51 1653 65
1665 2 1676 6
1677 12 1682 1This confirms that, as for fibrils, a specific molecular
recognition between the soluble species and aggregated
polypeptides underlies IBs-promoted fibril seeding.
The morphology of the aggregates in seeded and non-
seeded reactions was analyzed by transmission electronic
microscopy (TEM) to make sure that the observed in-
crease in aggregation rates results from a faster growth
of amyloid material and not from a rapid formation of
amorphous assemblies. As shown in Figure 5, regular
fibrillar structures were observed in all cases. Interest-
ingly, the morphology of the fibrils formed by seeding
with fibrils and IBs of the same protein were similar.
Overall, the data allow concluding that the selective
intra- and inter-molecular contacts that characterize
yeast prions fibrils are established as well by at least a
fraction of the polypeptide chains embedded in the
intracellular aggregates formed by these proteins in
bacteria.
Sup35-NM IBs are infectious
The Sup35 protein is an eukaryotic release factor, which
is required for translation termination in yeast [36,37].
In contrast to [psi-] cells, where the Sup35 protein is
soluble and functional, [PSI+] cells exhibit a nonsense
suppressor phenotype due to reduced translation ter-
mination efficiency as consequence of the sequestration
of native Sup35 into insoluble amyloid structures
[38,39]. Both the cellular content of yeast [PSI+] cells
and the amyloid fibrils formed in vitro by purified and
soluble Sup35-NM are infectious and suffice to promote
the transformation of the [psi-] phenotype into the [PSI+]
if they enter the cell [40].
The biophysical characterization of Sup35-NM and
Ure2p aggregates suggests that these proteins might get
access to prion conformations when expressed recombi-
nantly in bacteria. As described above, in the case of
Sup35-NM this property can be assessed by monitoring
the conversion of [psi-] yeast cells into [PSI+] ones. To
test this possibility, we fractionated bacterial cells
expressing Sup35-NM. The resulting soluble and inso-
luble fractions were used to transform spheroplasts of a
[psi-] yeast strain as described in the Methods section.ectra of purified E. coli Sup35-NM and Ure2p IBs
7°C
Ure2p IBs
Band (cm-1) Area (%) Structure
1617 8 Tyrosine ring
1629 26 β-sheet (inter-molecular)
1650 45
loop/β-turn/bend/α-helix1664 10
1677 11
Figure 3 Specific amyloid dyes staining of yeast prion IBs. (A)
CR spectral changes in the presence of each IB; displaying the
characteristic red-shift in λmax and intensity increase in CR spectra in
the presence of IBs. (B) Difference absorbance spectra of CR in
presence and absence of IBs showing the characteristic amyloid
band at 541 nm for both yeast proteins. (C) Fluorescence emission
spectrum of Th-T in the presence of each IB when excited at
445 nm; note the characteristic maximum at ~ 480 nm upon binding
to amyloid structures. (D) Yeast prions IBs stained with Th-S and
observed at 40x magnification by phase contrast and fluorescence
microscopy displaying the green fluorescence characteristic of
amyloid structures.
A
B
Figure 4 Aggregation kinetics of Sup35-NM and Ure2p. The
aggregation reactions of 20 μM yeast prionogenic proteins were
carried out under agitation at 37°C. 2 μM of in vitro formed fibrils
(representing 10% of the final protein concentration) or IBs (at a final
OD350nm of 0.125) were used for seeding and cross-seeding assays.
The fibrillar fraction of Sup35-NM (A) and Ure2p (B) is represented as
a function of time. The formation of Sup35-NM and Ure2p amyloid
fibrils are accelerated only in the presence of pre-aggregated
homologous protein, either fibrils or IBs.
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spectrin SH3 domain (MAXF-SH3) [41] were processed
in the same manner as a control, to make sure that
phenotypic conversion is not caused by endogenous
bacterial material or by the presence of a generic
aggregation-prone protein in the transformation solu-
tion. A pESC-URA3 plasmid that allows selecting for the
reduced fraction of transformed cells by uracil
auxotrophy was added to each of the fractions. Upon
spheroplast transformation, yeast cells were grown in
uracil-deprived plates. Subsequently, they were streaked
in ¼YPD plates. On these plates, [psi-] cells are of an in-
tense red color whereas [PSI+] cells appear white or
pink, depending if they convert to strong or weak [PSI+]
strains, respectively [42]. No [PSI+] colonies were
observed for transformations with any of the fractions of
MAXF-SH3 expressing cells. In contrast, transformation
with the soluble and insoluble fractions of Sup35-NM
expressing bacteria resulted in a 1.7% and 3.5% of [PSI+]
colonies, respectively (Figure 6 and Additional file 1:
Table S1). These results are reminiscent of those recently
reported by Hochschild and co-workers using a fusion of
a Sup35-NMR2E2 variant, containing extra copies of the
critical oligopeptide repeat region and displaying an
increased propensity to convert spontaneously into the
prion form in yeast [43], to GFP. They convincingly
demonstrated the formation of prionic variants of this
protein fusion in bacteria [44]. In our study, we confirmedthis behaviour using the wild type Sup35-NM domain
without any mutation or fusion that might modify its
intrinsic aggregation or conversion propensity [45].
An important difference between the results in both
studies is that in the case of the Sup35-NMR2E2 -GFP
fusion, the co-expression of the yeast New1 prionogenic
protein in bacteria appeared as a requirement for prion
formation. In contrast, our data argue that the natural
bacterial protein machinery suffices to support the for-
mation of prionic conformations, without a requirement
for exogenous factors. This apparent discrepancy in the
genetic background required for prion formation in
bacteria might arise, among other reasons, from the fact
that, in our hands, the Hochschild fractionation protocol
Table 2 Kinetic parameters of Sup35-NM and Ure2p aggregation reactions
Protein Parameters Non seeded Sup35-NM Fibrils Sup35-Nm IBs Ure2p IBs
Sup35-NM kn /10
6s-1 0.35 1.07 1.00 0.45
ke /M
-1s-1 37.54 36.08 36.67 36.07
cke /106s-1 750.83 721.50 733.33 721.33
t0 /s 124.0 102.5 98.6 123.0
t1/2 /s 169.9 150.1 149.6 171.0
t1 /s 215.8 197.8 200.7 219.1
Protein Parameters Non seeded Ure2p Fibrils Ure2p IBs Sup35-IBs
Ure2p kn/10
6s-1 2.13 11.46 14.24 2.62
ke /M
-1s-1 22.33 23.40 21.49 22.53
cke /106s-1 446.67 468.00 429.83 450.50
t0 /s 122.9 60.8 54.9 114.5
t1/2 /s 199.9 131.2 129.5 190.3
t1 /s 276.8 201.6 204.2 266.0
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that, according to their amyloid-like properties, the poly-
peptides embedded in these aggregates might contribute
significantly to infectivity. To confirm this point, we puri-
fied Sup35-NM IBs from the insoluble fraction of cells
cultured at 37°C and transformed them in [psi-] yeast
spheroplasts. [PSI+] strain conversion occurred at a fre-
quency of 5.6%. 65% of the transformed cells exhibited a
weak pink [PSI+] phenotype and the rest where white
(Figure 6 and Additional file 1: Table S1). Both Sup35-NM
IBs induced weak and strong [PSI+] phenotypes could be
cured when the transformed yeast cells were transiently
grown on a medium containing guanidine hydrochloride
(Figure 7). Moreover, when cellular extracts of [PSI+]
yeast cells resulting from IBs transformation were used to
transform [psi-] spheroplasts, 40% of the resulting colonies
converted to [PSI+]. These two features are characteristic
of [PSI+] strains and support an infective prion nature for
at least a fraction of the protein embedded in Sup35-NM
IBs. Overall, independently of methodological differences,
the data in the two studies converge to demonstrate that
the bacterial cytosol supports the formation of infective
amyloid-like structures.
Temperature dependence of the infectious properties of
Sup35-NM aggregates
It is postulated that the existence of distinct amyloid con-
formations of Sup35-NM accounts for the different [PSI+]
phenotypes that this prionogenic protein induces in yeast
[40,46,47]. In vitro, the temperature at which the aggrega-
tion of prionogenic proteins occurs might influence the
conformational properties of the resulting fibrils [27].
Accordingly, Weissman and co-workers demonstrated
that Sup35-NM fibrils formed in vitro at differenttemperatures rendered different [PSI+] phenotypes when
transformed into [psi-] cells. Fibrils formed at 4°C resulted
in a majority of [PSI+] cells displaying a strong (white)
phenotype whereas fibrils formed at 37°C rendered mostly
weak (pink) strains [40]. This result is in agreement with
our observation that most of the [PSI+] yeast strains
obtained after transformation with the content of bacterial
cells expressing Sup35-NM at 37°C displayed a weak
phenotype. We wondered if, by analogy to fibrils, cultiva-
tion of Sup35-NM expressing cells at lower temperature
would result in a significant increase of transformed cells
displaying a strong phenotype. To this aim, Sup35-NM
was expressed in bacterial cells grown at 18°C. First, we
addressed if production at lower temperature modifies the
distribution of recombinant Sup35-NM between the
soluble and insoluble fractions. As it can be seen in
Figure 8A, at 18°C the fraction of Sup35-NM protein
residing in the insoluble fraction is reduced by about five-
fold relative to that observed at 37°C, representing 8% of
the total recombinant protein. This solubilizing effect of
reduced temperature is well-documented for the expres-
sion of different model proteins [48]. Still, when the cellu-
lar fractions of these bacterial cells were used to transform
[psi-] spheroplasts, the conversion efficiency into [PSI+]
phenotypes was about five-fold higher for the insoluble
fraction than for the soluble one (Figure 6 and Additional
file 1: Table S1), arguing that Sup35-NM aggregates are
enriched in prion conformations relative to the corre-
sponding soluble species. Interestingly enough, the reduc-
tion in the production temperature results in a significant
increase in the proportion of white colonies (44%) among
[PSI+] cells (Figure 6 and Additional file 1: Table S1), rela-
tive to those observed at 37°C (25%). These data suggest
that, in principle, one can modulate the infective
Figure 5 Sup35-NM and Ure2p amyloid fibrils. Morphology of
Sup35-NM (A) and Ure2p (B) amyloid-like aggregates observed at
the final time point of the aggregation kinetics. Fibrils in un-seeded,
seeded and cross-seeded reactions were monitored by transmission
electronic microscopy.
Figure 6 Infectivity of Sup35-NM IBs. Induction of different [PSI+]
strains upon transformation of a [psi-] yeast strain with the soluble
(S), insoluble (I) fractions of E. coli cells expressing Sup35-NM protein
at 18 and 37°C or purified Sup35-NM IBs. After PEG transformation
with the indicated material, yeast cells were recovered on SD-URA
and randomly selected colonies were spotted onto ¼ YPD plates to
identify [PSI +] converted colonies. [psi-] and [PSI+] columns
correspond to the parental negative and positive control strains.
Transformation with the bacterial material induced pink (weak) and
to white (strong) [PSI+] phenotypes. Representative images of spots
corresponding to distinct strains are shown for each transformed
material (see Additional file 1: Table S1 for quantitative data).
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tuning the production conditions. In an effort to decipher
the conformational determinants of the differential infect-
ive properties of 37 and 18°C insoluble fractions, we puri-
fied IBs from the low temperature insoluble fraction,
analyzed their FT-IR in the amide I region of the spectra
and compared it with the one of IBs obtained at 37°C(Figure 8B). The shapes of both spectra were fairly similar.
This is in agreement with previous data in which we show
that changes in the temperature of aggregation of Sup35-
NM fibrils do not induce dramatic changes in their
secondary structure content, as assessed by FT-IR [27].
Nevertheless, certain differences in the contribution of the
spectral components to the main spectra could be
detected. In particular, the ratio between the contribution
of the band at 1628–1629 cm-1 and that at 1652–
1653 cm-1 is higher in the IBs formed at 18°C (0.56) than
in the IBs formed at 37°C (0.32), indicating a relative en-
richment in intermolecular β-sheet in the 18°C aggregates
[49] (Table 1). However, it is important to note that, des-
pite the differences detected in IBs secondary structure
content might contribute to the observed phenotypic differ-
ences between insoluble fractions, they might also be
caused by more subtle conformational features to which
FT-IR is blind, as shown for Sup35-NM amyloid fibrils [13].
Conclusions
Prions are misfolded, self-propagating, infectious pro-
teins. The bacterial IBs formed by HET-s PFD have been
shown to display an amyloid fold and to be infective
[19,20]. We show here that the IBs formed by the yeast
Ure2p and Sup35-NM prionogenic proteins have an
amyloid nature, while confirming the previous observa-
tion that bacteria supports the formation of Sup35-NM
prion conformations. Moreover, we prove that a major
fraction of the recombinant infective species is embed-
ded in IBs. The formation of infectious prion folds in
Figure 7 Curing the Sup35-NM IBs induced [PSI+] phenotype.
Comparison of spots of control [psi-] and [PSI+] strains with cells
displaying weak and strong [PSI+] phenotypes obtained by infection
with Sup35-NM IBs. Cells were spotted on ¼ YPD before (left) and
after (right) culture on a medium containing 3 mM GdnHCl.
Figure 8 Solubility and conformational properties of Sup35-NM
as a function of the temperature. (A) Western blot of the soluble
and insoluble fractions of cells expressing Sup35-NM at 18 and 37°C
detected with anti-histag antibody and quantified by Quantity One
software. (B) Comparative analysis of the secondary structure of
Sup35-NM IBs formed at 18°C and 37°C as determined FT-IR
spectroscopy in the amide I region of the spectrum. Empty circles,
solid thick lines and solid thin lines show the absorbance spectra,
the sum of individual spectral components and the deconvolved
component bands, respectively.
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as illustrated here using different growth temperatures.
Since proteins accumulate in IBs at high levels and these
biological particles are easily purified, it is suggested that
they might become a convenient source to obtain prion
particles exhibiting strain diversity. Besides, prion produ-
cing bacterial cells can potentially be used to develop
screens for anti-prion drugs; an approach already vali-
dated in yeast models [50,51].
Methods
Protein expression and purification
Plasmids encoding Sup35-NM residues 1 to 254 (NM)
C-terminally tagged with 7x-histidine and Ure2p
N-terminally tagged with 6x-histidine have been
described previously [13,52,53]. The histidine tag does
not affect the biological activity of Sup35-NM and Ure2p
in Saccaromyces cerevisiae [13,54]. The plasmids were
transformed into BL21(DE3) pLysS E. coli cells. For
protein expression, 10 mL overnight culture of trans-
formed cells was used to inoculate 2 L of DYT
medium, which was further incubated at 37°C and
250 rpm. At an OD600nm of 0.5, protein expression was
induced with 1 mM of isopropyl-1-thio-β-D-galacto-
pyranoside (IPTG) at 37°C for 3 h and 14 h for solubleprotein and IBs purification, respectively. The cultures
were centrifuged at 8 000 xg for 10 min, then resus-
pended in 20 mL of deionized water, centrifuged at
15 000 xg for 10 minutes and the cell pellet was frozen at
−80°C. For expression experiments at low temperature,
cells were initially grown at 37°C until an OD600nm of 0.4,
transferred to 18°C for 20 min, induced with 1 mM IPTG
and incubated for 14 h.
Ure2p and Sup35-NM proteins were purified from the
soluble and insoluble cell fractions, respectively, essen-
tially as previously described [27]. For lysis, cells were
resuspended in 5 mL of deionized water and 45 mL of
non-denaturing washing buffer (20 mM TrisHCl at pH
8.0, 0.5 M NaCl) was further added. The cell suspension
was placed under gentle agitation for 15 min. Finally, the
samples were sonicated with a Branson SonifierW ultra-
sonic cell disruptor for 3 min on ice. Soluble and insol-
uble fractions were separated after cell lysis by
centrifugation at 15 000 xg for 30 minutes. When
required, the insoluble fraction was resuspended in de-
naturing washing buffer. Affinity chromatography on
FF-Histrap resin (Amersham, Uppsala, Sweden) under
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6 M GdnHCl, and 20 mM or 500 mM imidazole for
washing and elution buffer, respectively) and non-
denaturing conditions (20 mM TrisHCl at pH 8.0,
0.5 M NaCl, and 20 mM or 500 mM imidazole for wash-
ing and elution buffer, respectively) was used for Sup35-
NM and Ure2p purfication, respectively. Buffer was
exchanged by gel filtration on Sephadex G-25 column
(Amersham, Uppsala, Sweden) for native buffer (50 mM
TrisHCl and 150 mM NaCl at pH 7.4).
Sup35-NM and Ure2p IBs purification
IBs were purified from induced cell extracts by
detergent-based procedures as previously described [16].
Briefly, cells in a 10 mL culture were harvested by cen-
trifugation at 12 000 xg (at 4°C) for 15 min and resus-
pended in 200 μL of lysis buffer (50 mM TrisHCl pH
8.0, 1 mM EDTA, 100 mM NaCl), plus 30 μL of
100 mM protease inhibitor PMSF and 6 μL of a 10 mg/
mL lysozyme solution. After 30 min of incubation at
37°C under gentle agitation, NP-40 was added at 1%
(v/v) and the mixture was incubated at 4°C for 30 min.
Then, 3 μL of DNase I and RNase from a 1 mg/mL
stock (25μg/mL final concentration) and 3 μL of 1 M
MgSO4 were added and the resulting mixture was fur-
ther incubated at 37°C for 30 min. Protein aggregates
were separated by centrifugation at 12 000 xg for 15 min
at 4°C. Finally, IBs were washed once with the same
buffer containing 0.5% Triton X-100 and once with ster-
ile native buffer. After a final centrifugation at 12 000 xg
for 15 min, pellets were stored at −20°C until analysis.
The frozen pellets were reconstituted in native buffer.
SDS-PAGE analysis revealed that in all cases the yeast
proteins were the major polypeptidic components of the
aggregates.
Fibril formation: Aggregation kinetics and seeding assays
For aggregation reactions, 20 μM of soluble Sup35-NM
and Ure2p in native buffer were placed under agitation
(~750 rpm with micro-stir bars) at 25°C. Conversion of
soluble species to aggregates was monitored by quantifi-
cation of the relative Th-T fluorescence at 480 nm when
exciting at 445 nm. In the seeding assay, a solution of
yeast prion IBs (to a final OD350nm = 0.125) or 2 μM of
preformed fibrils was also added at the beginning of the
reaction. Cross-seeding assays were performed in the
same manner. Yeast prions aggregation process, as other
related amyloid processes, may be modeled as an auto-
catalytic reaction using the equation f= (ρ{exp[(1 + ρ)kt]-
1})/{1 + ρ*exp[(1 + ρ)kt]} under the boundary condition
of t= 0 and f= 0, where k= kea (when a is the protein
concentration) and ρ represents the dimensionless value
to describe the ratio of kn to k. By non-linear regression
of f against t, values of ρ and k can be easily obtained,and from them the rate constants, ke (elongation con-
stant) and kn (nucleation constant). The extrapolation of
the growth portion of the sigmoid curve to abscissa
(f= 0), and to the highest ordinate value of the fitted
plot, afforded two values of time (t0 and t1), which cor-
respond to the lag time and to the time at which the ag-
gregation was almost complete [9,27,55].
Western blots
For Western blotting, bacterial cells were resuspended
in lysis buffer and sonicated with a Branson SonifierW
ultrasonic cell disruptor for 3 min on ice. The cellular
extract was centrifuged at 12 000 xg for 30 min. The sol-
uble fraction was separated and pellet was resuspended
exactly in the same volume of lysis buffer. To 50 μL of
the soluble and resuspended insoluble fractions it was
added 25 μL of loading buffer (180 mM Tris–HCl pH 7,
30% glycerol, 0.05% bromophenol blue, 9% sodium
dodecyl sulfate (SDS) and 15% β-mercaptoethanol) and
the mixture was heated at 95°C for 10 minutes. Insoluble
and soluble fractions were resolved on 15% SDS–PAGE
gels, transferred on to PVDF membranes, and recombin-
ant proteins detected with a polyclonal anti-histag anti-
body. The membranes were developed with the ECL
method [56]. The proportion of proteins in each fraction
was determinated using Quantity-One analysis software
(Bio-Rad, Hercules, CA, USA).
Spheroplast preparation for transformation
Yeast cells culture
Yeast strains L1749 (MATα ade1-14 ura3-52 leu2-3,112
trp1-289 his3-200, [psi-], [PIN+]) and L1762 (MATα
adel-14 ura3-52 leu2-3,112 trp1-289 his3-200, Strong
[PSI+], [PIN+]) were kindly provided by Susan Liebman.
Yeast strains were grown in solid YEPD medium for
48 h at 30°C; then a colony was inoculated in 10 mL li-
quid YEPD medium and incubated overnight at 30°C
and agitation of 250 rpm. 5 mL of this culture were used
to inoculate 50 mL of liquid YEPD at 30°C and 250 rpm.
When an OD600nm = 0.5 was reached, the culture was
centrifuged at 1 500 xg and room temperature for
10 min. Cells were successively washed with 20 mL of
sterile water and 1 M sorbitol, and centrifuged at 1 500
xg and room temperature for 5 min. Yeast cells were
resuspended in SCE buffer (1 M sorbitol, 10 mM EDTA,
10 mM DTT, 100 mM sodium citrate at pH 5.8) and
divided in 2 tubes.
Lyticase preparation
Lyticase from Arthrobacter luteus obtained as lyophilized
powder, ≥200 units/mg solid (L4025: Sigma) was pre-
pared at a final concentration of 10 000 unitsmL-1 in
phosphate buffer at pH 7.4 with 50% glycerol and kept
at −80°C.
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The first yeast cell tube was used to calculate the opti-
mal spheroplast lyticase digestion time, according to the
provider instructions. The second one was incubated
with 10 μL of lyticase at 30°C until 85-90% of sphero-
plasts were reached. The spheroplasts solution was then
centrifuged at 750 xg and room temperature for 10 min.
The spheroplasts were gently resuspended and washed
successively with 10 mL of 1 M sorbitol and STC buffer
(1 M sorbitol, 10 mM CaCl2 and 10 mM TrisHCl, pH
7.4), and centrifuged at 750 xg and room temperature
for 10 min. Finally, the spheroplasts were gently resus-
pended in 100 μL of STC and immediately used.
Spheroplast transformation
25 μL of pelleted spheroplats resuspended in STC buffer
were mixed with 3μL of sonicated soluble, insoluble
fractions or IBs of Sup35-NM, URA3-marked plasmid
(pRS316) (20 μg/mL) and salmon sperm DNA (100 μg/
mL). Fusion was induced by addition of 9 volumes of
PEG buffer (20% (w/v) PEG 8000, 10 mM CaCl2, 10 mM
TrisHCl at pH 7.5) for 30 min. Cells were centrifuged at
750 xg and room temperature for 10 min, and resus-
pended in SOS buffer (1 M sorbitol, 7 mM CaCl2, 0.25%
yeast extract, 0.5% bacto-peptone), incubated at 30°C for
30 min and plated on synthetic medium lacking uracil
overlaid with top agar (2.5% agar).
Analysis of prion phenotypes
After growth on synthetic medium lacking uracil (for
>5 days), the efficiency of conversion from [psi-] to [PSI+]
was tested by the following colour assay. Transformants
were randomly selected and streaked onto ¼ YPD plates
to enhance the colour phenotype. After 3 days the
streaked colonies were classified as strong [PSI+] (white),
weak [PSI+] (pink) and [psi-] (red) strains. The obtained
conversion percentages result from the analysis of >500
colonies for each transformation assay.
Conversion from [PSI+] to [psi-] strains
Yeast strains with different phenotypes were grown in
YEPD medium containing 3 mM of GdnHCl for 48 h at
30°C to cure the [PSI+] phenotype. The conversion from
[PSI+] to [psi-] phenotype was assessed by spotting cells
onto ¼ YPD plates.
Secondary structure determination
ATR FT-IR spectroscopy analyses of Sup35-NM and
Ure2p IBs were performed using a Bruker Tensor 27
FT-IR Spectrometer (Bruker Optics Inc) with a Golden
Gate MKII ATR accessory. Each spectrum consists of 16
independent scans, measured at a spectral resolution of
1 cm-1 within the 1700–1500 cm-1 range. All spectral
data were acquired and normalized using the OPUSMIR Tensor 27 software. FT-IR spectra were fitted to
five overlapping Gaussian curves and the amplitude,
centre, and bandwidth at half of the maximum ampli-
tude and area of each Gaussian function were calculated
using a nonlinear peak fitting program (PeakFit package,
Systat Software, San Jose, CA).
Chemical denaturation
For stability assays, purified IBs were prepared at
OD350nm=1 in native buffer containing selected concen-
trations of guanidine hydrochloride (GdnHCl) ranging
from 0 to 8 M. The reactions were allowed to reach equi-
librium by incubating them for 20 h at room temperature.
The fraction of soluble protein (fS) was calculated from
the fitted values using equation: fS = 1-((yS-y)/(yS-yA)),
where yS and yA are the absorbance at 350 nm of the sol-
uble and aggregated protein, respectively, and y is the ab-
sorbance of the protein solution as a function of the
denaturant concentration.
The value m1/2 was calculated as the denaturant con-
centration at which fS = 1/2. OD350nm changes were
monitored with a Cary400 Varian spectrophotometer.
Binding of amyloid dyes to Sup35-NM and Ure2p IBs and
amyloid fibrils
The interaction of 10 μM of Congo-Red (CR) with Sup35-
NM and Ure2p IBs and fibrils was tested using a Cary100
UV/Vis spectrophotometer (Varian, Palo Alto, CA, USA)
by recording the absorbance spectra from 375 nm to
675 nm using a matched pair of quartz cuvettes of 1 cm
optical length placed in a thermostated cell holder at 25°C.
In order to detect the typical amyloid band at ~541 nm, dif-
ferential CR spectra in the presence and absence of protein
were used.
The binding of 25 μM of Thioflavin-T (Th-T) to
Sup35-NM and Ure2p was recorded using a Cary Eclipse
spectrofluorometer (Varian, Palo Alto, CA, USA) with
an excitation wavelength of 445 nm and emission range
from 470 nm to 570 nm at 25°C in native buffer. For the
staining assays with Thioflavin-S (Th-S), Sup35-NM and
Ure2p IBs were incubated for 1 h in the presence of
125 μM of dye. After centrifugation (14 000 xg for
5 min), the precipitated fraction was placed on a
microscope slide and sealed. Images of Sup35-NM and
Ure2p IBs and fibrils bound to Th-S were obtained at
40-fold magnification under UV light or using phase
contrast in a Leica fluorescence microscope (Leica
DMRB, Heidelberg, Germany).
Transmission electronic microscopy
Fibrils containing solutions were placed on carbon-
coated copper grids, and left to stand for 5 min. The
grids were washed with distilled water and stained with
2% (w/v) uranyl acetate for another two minutes before
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microscope (Hitachi, Tokyo, Japan) operating at acceler-
ating voltage of 75 kV.
Additional file
Additional file 1: Table S1. Apparition frequencies of weak and strong
[PSI+] phenotypes in the transformation of [psi-] yeast strain with the
soluble, insoluble fractions of E. coli cells expressing Sup35-NM protein at
18°C and 37°C or purified Sup35-NM IBs.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SV and RS supervised the project, designed the study and drafted the
manuscript. AE carried out most of the experiments. AVP participated in the
experimental work. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants BFU2010-14901 from Ministerio de
Ciencia e Innovación (Spain) and 2009-SGR 760 from AGAUR (Generalitat de
Catalunya). RS is beneficiary of a contract from the Ramón y Cajal
Programme from Ministerio de Ciencia e Innovación. SV has been granted
an ICREA ACADEMIA award (ICREA).
Author details
1Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de
Barcelona, E-08193, Bellaterra, Spain. 2Departament de Bioquímica i Biologia
Molecular, Facultat de Ciències, Universitat Autònoma de Barcelona, E-08193,
Bellaterra, Spain. 3Departament de Fisicoquímica, Facultat de Farmàcia,
Universitat de Barcelona, Avda. Joan XXIII s/n, E-08028, Barcelona, Spain.
4Institut de Nanociència i Nanotecnologia (IN2UB), Barcelona, Spain.
Received: 5 February 2012 Accepted: 27 May 2012
Published: 25 June 2012
References
1. Aguzzi A, Weissmann C: Prion diseases. Haemophilia 1998, 4(4):619–627.
2. Wickner RB, Edskes HK, Shewmaker F, Nakayashiki T: Prions of fungi:
inherited structures and biological roles. Nat Rev Microbiol 2007, 5(8):
611–618.
3. McGlinchey RP, Kryndushkin D, Wickner RB: Suicidal [PSI+] is a lethal yeast
prion. Proc Natl Acad Sci U S A 2011, 108(13):5337–5341.
4. Wickner RB, Edskes HK, Bateman D, Kelly AC, Gorkovskiy A: The yeast prions
[PSI+] and [URE3] are molecular degenerative diseases. Prion 2011, 5(4).
5. Halfmann R, Jarosz DF, Jones SK, Chang A, Lancaster AK, Lindquist S: Prions
are a common mechanism for phenotypic inheritance in wild yeasts.
Nature 2012, 482(7385):363–368.
6. Shorter J, Lindquist S: Prions as adaptive conduits of memory and
inheritance. Nat Rev Genet 2005, 6(6):435–450.
7. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE: Prion protein biology. Cell
1998, 93:337–348.
8. Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE: Pathway
complexity of prion protein assembly into amyloid. J Biol Chem 2002, 277
(24):21140–21148.
9. Sabate R, Castillo V, Espargaro A, Saupe SJ, Ventura S: Energy barriers for
HET-s prion forming domain amyloid formation. FEBS J 2009, 276
(18):5053–5064.
10. Patino MM, Liu JJ, Glover JR, Lindquist S: Support for the prion hypothesis
for inheritance of a phenotypic trait in yeast. Science 1996, 273(5275):
622–626.
11. Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, DeArmond SJ,
Prusiner SB: Synthetic mammalian prions. Science 2004, 305(5684):673–676.
12. Castilla J, Saa P, Hetz C, Soto C: In vitro generation of infectious scrapie
prions. Cell 2005, 121(2):195–206.
13. Tanaka M, Chien P, Naber N, Cooke R, Weissman JS: Conformational
variations in an infectious protein determine prion strain differences.
Nature 2004, 428(6980):323–328.14. Sabate R, de Groot NS, Ventura S: Protein folding and aggregation in
bacteria. Cell Mol Life Sci 2010, 67(16):2695–2715.
15. de Groot NS, Sabate R, Ventura S: Amyloids in bacterial inclusion bodies.
Trends Biochem Sci 2009, 34(8):408–416.
16. Morell M, Bravo R, Espargaro A, Sisquella X, Aviles FX, Fernandez-Busquets X,
Ventura S: Inclusion bodies: specificity in their aggregation process and
amyloid-like structure. Biochim Biophys Acta 2008, 1783(10):1815–1825.
17. Carrio M, Gonzalez-Montalban N, Vera A, Villaverde A, Ventura S: Amyloid-
like properties of bacterial inclusion bodies. J Mol Biol 2005, 347:
1025–1037.
18. Wang L, Maji SK, Sawaya MR, Eisenberg D, Riek R: Bacterial inclusion
bodies contain amyloid-like structure. PLoS Biol 2008, 6(8):e195.
19. Sabate R, Espargaro A, Saupe SJ, Ventura S: Characterization of the
amyloid bacterial inclusion bodies of the HET-s fungal prion. Microb Cell
Fact 2009, 8:56.
20. Wasmer C, Benkemoun L, Sabate R, Steinmetz MO, Coulary-Salin B, Wang L,
Riek R, Saupe SJ, Meier BH: Solid-state NMR spectroscopy reveals that E.
coli inclusion bodies of HET-s(218–289) are amyloids. Angew Chem Int Ed
Engl 2009, 48(26):4858–4860.
21. Ritter C, Maddelein ML, Siemer AB, Luhrs T, Ernst M, Meier BH, Saupe SJ,
Riek R: Correlation of structural elements and infectivity of the HET-s
prion. Nature 2005, 435(7043):844–848.
22. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg
D: Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005,
435(7043):773–778.
23. Fernandez-Busquets X, de Groot NS, Fernandez D, Ventura S: Recent
structural and computational insights into conformational diseases. Curr
Med Chem 2008, 15(13):1336–1349.
24. Fink AL: Protein aggregation: folding aggregates, inclusion bodies and
amyloid. Fold Des 1998, 3:R9–23.
25. Ami D, Natalello A, Taylor G, Tonon G, Maria Doglia S: Structural analysis of
protein inclusion bodies by Fourier transform infrared
microspectroscopy. Biochim Biophys Acta 2006, 1764(4):793–799.
26. Dasari M, Espargaro A, Sabate R, Lopez Del Amo JM, Fink U, Grelle G,
Bieschke J, Ventura S, Reif B: Bacterial Inclusion Bodies of Alzheimer's
Disease beta-Amyloid Peptides Can Be Employed To Study Native-Like
Aggregation Intermediate States. ChemBioChem 2011, 12(3):407–423.
27. Sabate R, Villar-Pique A, Espargaro A, Ventura S: Temperature dependence
of the aggregation kinetics of Sup35 and Ure2p yeast prions.
Biomacromolecules 2012, 13(2):474–483.
28. Bousset L, Briki F, Doucet J, Melki R: The native-like conformation of Ure2p
in fibrils assembled under physiologically relevant conditions switches
to an amyloid-like conformation upon heat-treatment of the fibrils. J
Struct Biol 2003, 141(2):132–142.
29. Espargaro A, Sabate R, Ventura S: Kinetic and thermodynamic stability of
bacterial intracellular aggregates. FEBS Lett 2008, 582(25–26):3669–3673.
30. Bousset L, Thomson NH, Radford SE, Melki R: The yeast prion Ure2p retains
its native alpha-helical conformation upon assembly into protein fibrils
in vitro. EMBO J 2002, 21(12):2903–2911.
31. Hess S, Lindquist SL, Scheibel T: Alternative assembly pathways of the
amyloidogenic yeast prion determinant Sup35-NM. EMBO Rep 2007, 8
(12):1196–1201.
32. Caughey B, Raymond GJ, Callahan MA, Wong C, Baron GS, Xiong LW:
Interactions and conversions of prion protein isoforms. Adv Protein Chem
2001, 57:139–169.
33. Wickner RB, Taylor KL, Edskes HK, Maddelein ML, Moriyama H, Roberts BT:
Yeast prions act as genes composed of self-propagating protein
amyloids. Adv Protein Chem 2001, 57:313–334.
34. Serio TR, Lindquist SL: The yeast prion [PSI+]: molecular insights and
functional consequences. Adv Protein Chem 2001, 59:391–412.
35. Krebs MR, Morozova-Roche LA, Daniel K, Robinson CV, Dobson CM:
Observation of sequence specificity in the seeding of protein amyloid
fibrils. Protein Sci 2004, 13(7):1933–1938.
36. Frolova L, Le Goff X, Rasmussen HH, Cheperegin S, Drugeon G, Kress M,
Arman I, Haenni AL, Celis JE, Philippe M, et al: A highly conserved
eukaryotic protein family possessing properties of polypeptide chain
release factor. Nature 1994, 372(6507):701–703.
37. Stansfield I, Jones KM, Kushnirov VV, Dagkesamanskaya AR, Poznyakovski AI,
Paushkin SV, Nierras CR, Cox BS, Ter-Avanesyan MD, Tuite MF: The products
of the SUP45 (eRF1) and SUP35 genes interact to mediate translation
termination in Saccharomyces cerevisiae. EMBO J 1995, 14(17):4365–4373.
Espargaró et al. Microbial Cell Factories 2012, 11:89 Page 12 of 12
http://www.microbialcellfactories.com/content/11/1/8938. Liebman SW, Derkatch IL: The yeast [PSI+] prion: making sense of
nonsense. J Biol Chem 1999, 274(3):1181–1184.
39. Eaglestone SS, Cox BS, Tuite MF: Translation termination efficiency can be
regulated in Saccharomyces cerevisiae by environmental stress through
a prion-mediated mechanism. EMBO J 1999, 18(7):1974–1981.
40. Tanaka M, Collins SR, Toyama BH, Weissman JS: The physical basis of how
prion conformations determine strain phenotypes. Nature 2006, 442
(7102):585–589.
41. Castillo V, Espargaro A, Gordo V, Vendrell J, Ventura S: Deciphering the role
of the thermodynamic and kinetic stabilities of SH3 domains on their
aggregation inside bacteria. Proteomics 2010, 10(23):4172–4185.
42. Serio TR, Cashikar AG, Moslehi JJ, Kowal AS, Lindquist SL: Yeast prion [psi +]
and its determinant, Sup35p. Methods Enzymol 1999, 309:649–673.
43. Liu JJ, Lindquist S: Oligopeptide-repeat expansions modulate 'protein-
only' inheritance in yeast. Nature 1999, 400(6744):573–576.
44. Garrity SJ, Sivanathan V, Dong J, Lindquist S, Hochschild A: Conversion of a
yeast prion protein to an infectious form in bacteria. Proc Natl Acad Sci U
S A 2010, 107(23):10596–10601.
45. Bulone D, Masino L, Thomas DJ, San Biagio PL, Pastore A: The interplay
between PolyQ and protein context delays aggregation by forming a
reservoir of protofibrils. PLoS One 2006, 1:e111.
46. King CY, Diaz-Avalos R: Protein-only transmission of three yeast prion
strains. Nature 2004, 428(6980):319–323.
47. Diaz-Avalos R, King CY, Wall J, Simon M, Caspar DL: Strain-specific
morphologies of yeast prion amyloid fibrils. Proc Natl Acad Sci U S A 2005,
102(29):10165–10170.
48. Sorensen HP, Mortensen KK: Soluble expression of recombinant proteins
in the cytoplasm of Escherichia coli. Microb Cell Fact 2005, 4:1.
49. Gonzalez-Montalban N, Garcia-Fruitos E, Ventura S, Aris A, Villaverde A: The
chaperone DnaK controls the fractioning of functional protein between
soluble and insoluble cell fractions in inclusion body-forming cells.
Microb Cell Fact 2006, 5:26.
50. Bach S, Talarek N, Andrieu T, Vierfond JM, Mettey Y, Galons H, Dormont D,
Meijer L, Cullin C, Blondel M: Isolation of drugs active against mammalian
prions using a yeast-based screening assay. Nat Biotechnol 2003, 21
(9):1075–1081.
51. Bach S, Tribouillard D, Talarek N, Desban N, Gug F, Galons H, Blondel M: A
yeast-based assay to isolate drugs active against mammalian prions.
Methods 2006, 39(1):72–77.
52. DePace AH, Santoso A, Hillner P, Weissman JS: A critical role for
amino-terminal glutamine/asparagine repeats in the formation and
propagation of a yeast prion. Cell 1998, 93(7):1241–1252.
53. Ross ED, Baxa U, Wickner RB: Scrambled prion domains form prions and
amyloid. Mol Cell Biol 2004, 24(16):7206–7213.
54. Immel F, Jiang Y, Wang YQ, Marchal C, Maillet L, Perrett S, Cullin C: In vitro
analysis of SpUre2p, a prion-related protein, exemplifies the relationship
between amyloid and prion. J Biol Chem 2007, 282(11):7912–7920.
55. Sabate R, Gallardo M, Estelrich J: An autocatalytic reaction as a model for
the kinetics of the aggregation of beta-amyloid. Biopolymers 2003, 71
(2):190–195.
56. Morell M, Espargaro A, Aviles FX, Ventura S: Detection of transient
protein-protein interactions by bimolecular fluorescence
complementation: the Abl-SH3 case. Proteomics 2007, 7(7):1023–1036.
doi:10.1186/1475-2859-11-89
Cite this article as: Espargaró et al.: Yeast prions form infectious amyloid
inclusion bodies in bacteria. Microbial Cell Factories 2012 11:89.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
